Forget Zepbound: Eli Lilly's Next Weight-Loss Drug Could Be Its Biggest Blockbuster Yet
Can anyone stop Eli Lilly’s progress in the weight loss market?
Eli Lilly, the biggest player in the healthcare sector, has seen impressive returns on its investment in the anti-obesity market. Its lead product, Zepbound, has been a standout performer, boasting exceptional sales growth. However, the company has a number of promising pipeline drugs, one of which may surpass Zepbound in performance.
Zepbound's unique selling point is its dual action on GLP-1 and GIP gut hormones, a strategy that has yielded superior weight loss results compared to its main rival, Wegovy, which only stimulates GLP-1.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
